AI-Designed Recognition Proteins: Korean Urine Drug Test Targets Quantitative Results in 10 Seconds

If urine drug screening could provide quantitative results within ten seconds, law enforcement officers would not have to rely solely on colored lines on test strips for preliminary interpretation. According to South Korea’s Dong-A Science, a testing system combining AI-designed proteins with electrochemical sensing is advancing toward this goal, seeking to identify continually evolving emerging drugs more quickly.

The technology centers on designing selective binding proteins for target small molecules. When a specific substance in urine is captured by a protein, the binding event can be converted into an electrochemical signal, which a portable reader then uses to estimate its concentration. Compared with rapid test strips that provide only a positive or negative result, quantitative readings could theoretically be more useful for distinguishing concentrations near cutoff thresholds and tracking signal strength. However, the publicly available summary does not explain how AI participates in sequence design or how many rounds of experimental screening the candidate proteins undergo.

The work originated from the Public Safety Emergency Response Research program jointly promoted by South Korea’s Ministry of Science and ICT and Ministry of the Interior and Safety. In 2025, the two ministries designated the “Synthetic Biology-Based Simple Detection System for Emerging Drugs” as a new project, with the aim of improving the efficiency of on-site enforcement and investigations. The project is expected to receive approximately KRW 900 million in government research and development funding over two years.

Government solicitation materials show that the project targets benzodiazepine- and phencyclidine-class substances. It plans to develop two types of test kits and one compact reader, and to use human urine to assess accuracy, sensitivity, specificity, response time, and signal reproducibility. The research period runs from May 2025 through April 2027. Final objectives include reaching Technology Readiness Level 7, completing 100 reagent kits and two readers, and securing at least two patents.

A ten-second reading still cannot be directly equated with suitability for judicial determination. Urine has a complex composition, and prescription drugs, metabolites, and novel substances with similar structures may all cause cross-reactivity; different sampling times and concentrations can also affect results. The more appropriate role for a rapid kit is on-site screening, while positive or disputed results still need to be confirmed by laboratory methods such as chromatography and mass spectrometry.

Currently available public information primarily describes the research and development objectives. It has not yet provided the sample size, detection limit, blinded-testing design, or the sensitivity and specificity for each drug class, nor has it confirmed whether the ten-second performance has undergone independent validation using real urine samples under field conditions. These data, together with the ethical review of sample studies, manufacturing consistency, and the method by which regulatory authorities will recognize the results, will determine whether AI-designed proteins can move from laboratory components into actual drug-enforcement workflows.